Free Trial

Core Scientific (CORZ) Financials

Core Scientific logo
$11.28 +0.60 (+5.62%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$11.13 -0.15 (-1.37%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Core Scientific

Annual Income Statements for Core Scientific

This table shows Core Scientific's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Income / (Loss) Attributable to Common Shareholders
-1,315 -246 -2,146 47 -18
Consolidated Net Income / (Loss)
-1,315 -246 -2,146 47 -12
Net Income / (Loss) Continuing Operations
-1,315 -246 -2,146 47 -18
Total Pre-Tax Income
-1,314 -246 -2,163 63 -12
Total Operating Income
-19 8.96 -2,110 131 -6.33
Total Gross Profit
121 123 8.40 239 9.39
Total Revenue
511 502 640 544 54
Operating Revenue
511 502 640 544 54
Total Cost of Revenue
390 379 632 306 51
Operating Cost of Revenue
390 379 632 306 51
Total Operating Expenses
140 114 2,118 107 16
Selling, General & Admin Expense
110 94 213 60 15
Marketing Expense
9.97 7.02 13 4.06 1.77
Research & Development Expense
12 7.18 27 7.67 5.27
Other Operating Expenses / (Income)
3.81 0.03 0.00 0.00 -
Impairment Charge
0.00 4.41 1,881 37 0.00
Other Special Charges / (Income)
4.21 1.96 -16 -2.06 -5.88
Total Other Income / (Expense), net
-1,295 -255 -54 -68 -5.88
Interest Expense
0.49 -20 0.29 8.02 1.33
Interest & Investment Income
-37 -86 -97 -44 -4.44
Other Income / (Expense), net
-1,257 -189 43 -16 -0.11
Income Tax Expense
0.86 0.68 -17 16 0.00
Basic Earnings per Share
($4.39) ($0.65) ($6.30) $0.23 ($0.14)
Weighted Average Basic Shares Outstanding
255.83M 379.86M 340.65M 207.26M 157.60M
Diluted Earnings per Share
($4.39) ($0.65) ($6.30) $0.20 ($0.14)
Weighted Average Diluted Shares Outstanding
255.83M 379.86M 340.65M 233.31M 157.60M
Weighted Average Basic & Diluted Shares Outstanding
294.12M 177.60M 373.80M 0.00 -

Quarterly Income Statements for Core Scientific

This table shows Core Scientific's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
581 -266 -455 -805 211 -196 -41 -9.26 -0.39 -435 -435
Consolidated Net Income / (Loss)
581 -266 -455 -805 211 -196 -41 -9.26 -0.39 -435 -435
Net Income / (Loss) Continuing Operations
581 -266 -455 -805 211 -196 -41 -9.26 -0.39 -435 -435
Total Pre-Tax Income
581 -265 -455 -805 211 -195 -41 -9.13 -0.28 -456 -424
Total Operating Income
-43 -40 -41 6.58 55 3.93 -12 9.47 7.60 -636 -401
Total Gross Profit
8.21 4.76 -0.16 39 78 39 15 37 32 -47 -27
Total Revenue
80 94 95 141 180 142 113 127 121 121 163
Operating Revenue
80 94 95 141 180 142 113 127 121 121 163
Total Cost of Revenue
71 90 96 102 102 103 97 90 89 168 190
Operating Cost of Revenue
71 90 96 102 102 103 97 90 89 168 190
Total Operating Expenses
51 44 41 32 23 35 27 27 24 589 374
Selling, General & Admin Expense
40 36 34 26 14 24 24 24 22 39 43
Other Operating Expenses / (Income)
11 0.26 0.21 1.12 2.22 0.03 0.00 0.00 0.00 - -
Other Special Charges / (Income)
0.01 0.15 0.51 -0.27 3.82 3.80 -0.02 -0.76 -1.06 -4.32 -11
Total Other Income / (Expense), net
623 -225 -414 -811 156 -199 -29 -19 -7.89 180 -23
Interest Expense
0.00 - 0.32 0.12 0.05 1.07 -0.37 0.00 -21 0.29 0.00
Interest & Investment Income
2.19 -1.14 -7.07 -15 -14 -84 -2.20 0.04 -0.16 -22 -26
Other Income / (Expense), net
621 -224 -407 -796 170 -114 -27 -19 -28 202 3.17
Income Tax Expense
0.21 0.38 0.13 0.14 0.21 0.34 0.11 0.13 0.10 -21 11
Basic Earnings per Share
$1.44 $0.38 ($1.17) ($4.51) $0.91 ($0.52) ($0.11) ($0.02) $0.00 ($1.06) ($1.23)
Weighted Average Basic Shares Outstanding
315.19M 255.83M 292.49M 178.51M 230.95M 379.86M 382.48M 375.78M 375.42M 340.65M 354.20M
Diluted Earnings per Share
$1.25 $0.51 ($1.17) ($4.51) $0.78 ($0.52) ($0.11) ($0.02) $0.00 ($1.06) ($1.23)
Weighted Average Diluted Shares Outstanding
363.31M 255.83M 292.49M 178.51M 282.53M 379.86M 382.48M 375.78M 375.42M 340.65M 354.20M
Weighted Average Basic & Diluted Shares Outstanding
297.82M 294.12M 279.25M 258.22M 177.78M 177.60M 386.02M 382.61M 376.57M 373.80M 374.53M

Annual Cash Flow Statements for Core Scientific

This table details how cash moves in and out of Core Scientific's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Net Change in Cash & Equivalents
767 17 -79 123 1.81
Net Cash From Operating Activities
43 65 205 -57 -24
Net Cash From Continuing Operating Activities
43 65 205 -57 -24
Net Income / (Loss) Continuing Operations
-1,315 -246 -2,146 47 -12
Consolidated Net Income / (Loss)
-1,315 -246 -2,146 47 -12
Depreciation Expense
113 96 225 33 9.40
Amortization Expense
11 1.19 7.97 1.37 1.30
Non-Cash Adjustments To Reconcile Net Income
1,264 47 2,058 -75 4.95
Changes in Operating Assets and Liabilities, net
-30 167 60 -64 -27
Net Cash From Investing Activities
-95 -3.00 -591 -424 -15
Net Cash From Continuing Investing Activities
-95 -3.00 -591 -425 -15
Purchase of Property, Plant & Equipment
-95 -17 -384 0.00 0.00
Sale of Property, Plant & Equipment
0.00 14 0.00 0.00 -
Divestitures
0.00 0.00 11 - -
Other Investing Activities, net
0.00 0.00 -218 -59 -1.48
Net Cash From Financing Activities
820 -45 306 604 41
Net Cash From Continuing Financing Activities
820 -45 306 604 41
Repayment of Debt
-315 -45 -113 -49 -7.10
Repurchase of Common Equity
0.00 0.00 -32 - 0.00
Issuance of Debt
1,078 0.00 261 671 45
Issuance of Common Equity
55 0.00 0.00 - -
Other Financing Activities, net
1.50 0.00 190 -18 2.64
Cash Interest Paid
29 4.71 86 38 2.90
Cash Income Taxes Paid
-0.16 -0.37 5.76 9.62 0.00

Quarterly Cash Flow Statements for Core Scientific

This table details how cash moves in and out of Core Scientific's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-138 583 157 -17 45 5.77 -13 7.47 17 15 -103
Net Cash From Operating Activities
-41 14 5.71 1.20 22 22 5.43 18 20 116 -52
Net Cash From Continuing Operating Activities
-41 14 5.71 1.20 22 22 5.43 18 20 116 -52
Net Income / (Loss) Continuing Operations
581 -266 -455 -805 211 -196 -41 -9.26 -0.39 -435 -435
Consolidated Net Income / (Loss)
581 -266 -455 -805 211 -196 -41 -9.26 -0.39 -435 -435
Depreciation Expense
20 26 29 29 29 31 24 20 20 69 65
Amortization Expense
4.41 4.51 2.29 2.45 1.43 0.49 0.23 0.27 0.20 1.37 2.57
Non-Cash Adjustments To Reconcile Net Income
-662 225 431 807 -199 26 15 14 -7.76 356 390
Changes in Operating Assets and Liabilities, net
17 24 -1.46 -33 -20 159 7.52 -7.58 7.81 124 -74
Net Cash From Investing Activities
-93 -29 -31 -3.18 -32 2.36 -2.87 -0.62 -1.87 -139 -5.66
Net Cash From Continuing Investing Activities
-93 -29 -31 -3.18 -32 2.36 -2.87 -0.62 -1.87 -139 -5.66
Purchase of Property, Plant & Equipment
-88 -29 -31 -3.14 -32 -12 -2.87 -0.95 -1.54 -140 -5.22
Acquisitions
-5.00 - - - - - - - - - -
Net Cash From Financing Activities
-4.20 598 182 -15 54 -18 -15 -9.95 -1.02 38 -45
Net Cash From Continuing Financing Activities
-4.20 598 182 -15 54 -18 -15 -9.95 -1.02 38 -45
Repayment of Debt
-3.96 -15 -271 -11 -17 -22 -12 -9.95 -1.02 14 -78
Issuance of Debt
0.00 610 448 - 20 - - - 0.00 45 -0.08
Issuance of Common Equity
0.00 - - - 55 - - - 0.00 - -199
Other Financing Activities, net
-0.24 2.97 6.01 -4.10 -3.38 3.41 -3.41 - 0.00 11 231

Annual Balance Sheets for Core Scientific

This table presents Core Scientific's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Total Assets
1,599 712 808 2,439 0.02
Total Current Assets
904 97 85 757 0.00
Cash & Equivalents
836 50 16 118 0.00
Restricted Cash
0.78 19 36 14 -
Accounts Receivable
1.03 1.00 0.26 1.68 -
Other Current Assets
66 26 0.72 593 -
Plant, Property, & Equipment, net
556 585 691 0.00 0.00
Total Noncurrent Assets
139 30 31 1,682 0.02
Other Noncurrent Operating Assets
139 30 30 618 0.02
Total Liabilities & Shareholders' Equity
1,599 712 808 2,439 0.02
Total Liabilities
2,419 1,309 1,217 1,053 0.00
Total Current Liabilities
135 488 187 320 0.00
Short-Term Debt
16 124 36 104 -
Accounts Payable
19 155 54 12 0.00
Accrued Expenses
69 180 18 68 0.00
Current Deferred Revenue
18 9.83 78 136 -
Other Current Liabilities
12 20 0.77 0.00 -
Total Noncurrent Liabilities
2,284 821 1,030 733 0.00
Long-Term Debt
1,074 684 0.00 652 -
Capital Lease Obligations
98 37 0.72 62 -
Other Noncurrent Operating Liabilities
1,113 99 1,030 19 0.00
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-820 -597 -409 1,341 0.01
Total Preferred & Common Equity
-820 -597 -409 1,341 0.01
Preferred Stock
0.00 0.00 - - 0.00
Total Common Equity
-820 -597 -409 1,341 0.01
Common Stock
2,915 1,823 1,764 1,380 0.03
Retained Earnings
-3,735 -2,420 -2,174 -27 -0.01

Quarterly Balance Sheets for Core Scientific

This table presents Core Scientific's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
1,625 922 761 814 705 751 760 1,404
Total Current Assets
833 278 118 143 135 111 100 214
Cash & Equivalents
698 253 96 98 42 58 47 30
Restricted Cash
0.78 0.78 0.98 16 22 19 22 8.10
Accounts Receivable
1.02 6.24 4.68 1.11 1.11 1.26 0.18 3.07
Other Current Assets
133 18 16 28 34 33 31 173
Plant, Property, & Equipment, net
650 550 550 576 547 608 628 1,156
Total Noncurrent Assets
142 94 94 95 23 32 32 34
Other Noncurrent Operating Assets
142 94 94 93 21 29 30 33
Total Liabilities & Shareholders' Equity
1,625 922 761 814 705 751 760 1,404
Total Liabilities
1,807 1,651 1,845 1,132 1,124 1,143 1,169 1,331
Total Current Liabilities
196 77 75 138 313 187 215 1,289
Short-Term Debt
16 18 18 23 128 28 36 978
Accounts Payable
6.33 6.50 8.49 16 46 54 50 44
Accrued Expenses
95 32 29 68 56 41 59 102
Current Deferred Revenue
61 9.94 7.91 9.25 63 64 70 87
Other Current Liabilities
17 10 11 21 20 0.42 0.60 78
Total Noncurrent Liabilities
1,611 1,575 1,771 994 812 956 954 42
Long-Term Debt
1,072 475 527 557 680 0.05 - 0.00
Capital Lease Obligations
95 65 68 70 37 1.03 1.06 0.00
Other Noncurrent Operating Liabilities
445 1,035 1,176 368 95 955 953 42
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-182 -729 -1,084 -319 -419 -392 -409 73
Total Preferred & Common Equity
-182 -729 -1,084 -319 -419 -392 -409 73
Preferred Stock
0.00 0.00 0.00 0.00 - - - -
Total Common Equity
-182 -729 -1,084 -319 -419 -392 -409 73
Common Stock
2,973 2,740 1,931 1,891 1,806 1,791 1,777 1,739
Retained Earnings
-3,155 -3,470 -3,014 -2,210 -2,225 -2,183 -2,185 -1,739

Annual Metrics And Ratios for Core Scientific

This table displays calculated financial ratios and metrics derived from Core Scientific's official financial filings.

Metric 2024 2023 2022 2021 2020
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Growth Metrics
- - - - -
Revenue Growth
1.65% -21.54% 17.60% 904.71% 0.00%
EBITDA Growth
-1,298.35% 95.50% -1,320.57% 3,420.42% 0.00%
EBIT Growth
-610.67% 91.31% -1,889.85% 1,893.46% 0.00%
NOPAT Growth
-314.22% 100.42% -1,597.16% 2,327.02% 0.00%
Net Income Growth
-433.50% 88.52% -4,636.52% 487.61% 0.00%
EPS Growth
-575.38% 89.68% -3,250.00% 242.86% 0.00%
Operating Cash Flow Growth
-34.12% -68.27% 461.66% -138.73% 0.00%
Free Cash Flow Firm Growth
206.23% -158.53% 151.71% 0.00% 0.00%
Invested Capital Growth
-361.96% 142.17% -120.49% 14,197,256.16% 0.00%
Revenue Q/Q Growth
-8.52% 4.29% -21.99% 0.00% 0.00%
EBITDA Q/Q Growth
-15.51% 77.58% -35.42% 0.00% 0.00%
EBIT Q/Q Growth
-13.68% 64.30% -34.39% 0.00% 0.00%
NOPAT Q/Q Growth
-178.28% 101.42% -53.83% 0.00% 0.00%
Net Income Q/Q Growth
-5.61% 49.25% -30.00% 0.00% 0.00%
EPS Q/Q Growth
19.00% 45.38% -26.25% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-15.55% -59.15% 3.14% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth
-17.43% -343.69% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth
-10.28% -45.09% -141.92% 0.00% 0.00%
Profitability Metrics
- - - - -
Gross Margin
23.71% 24.57% 1.31% 43.87% 17.33%
EBITDA Margin
-225.72% -16.41% -286.28% 27.58% 7.87%
Operating Margin
-3.76% 1.78% -329.46% 24.15% -11.67%
EBIT Margin
-249.98% -35.75% -322.70% 21.20% -11.88%
Profit (Net Income) Margin
-257.50% -49.06% -335.20% 8.69% -22.52%
Tax Burden Percent
100.07% 100.28% 99.21% 75.01% 100.00%
Interest Burden Percent
102.94% 136.84% 104.70% 54.64% 189.62%
Effective Tax Rate
0.00% 0.00% 0.00% 24.99% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% -179.19% 9.52% -30,334.93%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% -378.53% -5.42% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% -260.48% -2.69% 0.00%
Return on Equity (ROE)
185.59% 48.99% -439.67% 6.83% 0.00%
Cash Return on Invested Capital (CROIC)
0.00% -333.65% 0.00% -190.48% 0.00%
Operating Return on Assets (OROA)
-110.48% -23.64% -127.29% 9.47% -42,913.33%
Return on Assets (ROA)
-113.81% -32.44% -132.22% 3.88% -81,373.33%
Return on Common Equity (ROCE)
185.59% 48.99% -419.64% 6.61% 0.00%
Return on Equity Simple (ROE_SIMPLE)
160.33% 41.29% 524.33% 3.53% 0.00%
Net Operating Profit after Tax (NOPAT)
-13 6.27 -1,477 99 -4.43
NOPAT Margin
-2.63% 1.25% -230.62% 18.11% -8.17%
Net Nonoperating Expense Percent (NNEP)
230.95% 66.45% 199.34% 14.94% 0.00%
Return On Investment Capital (ROIC_SIMPLE)
-3.65% 2.52% 396.55% - -
Cost of Revenue to Revenue
76.29% 75.43% 98.69% 56.13% 93.98%
SG&A Expenses to Revenue
21.63% 18.69% 33.31% 11.11% 26.86%
R&D to Revenue
2.32% 1.43% 4.21% 1.41% 9.73%
Operating Expenses to Revenue
27.47% 22.79% 330.77% 19.72% 29.00%
Earnings before Interest and Taxes (EBIT)
-1,277 -180 -2,066 115 -6.44
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-1,153 -82 -1,833 150 4.27
Valuation Ratios
- - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 20,547.95
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 20,547.95
Price to Revenue (P/Rev)
7.68 0.00 0.00 0.00 5.54
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 20,547.95
Enterprise Value to Revenue (EV/Rev)
8.37 0.00 0.00 0.00 5.54
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 70.32
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
99.65 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
6.74 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - -
Debt to Equity
-1.45 -1.42 -0.09 0.59 0.00
Long-Term Debt to Equity
-1.43 -1.21 0.00 0.52 0.00
Financial Leverage
-0.80 -0.76 0.69 0.50 0.00
Leverage Ratio
-1.63 -1.51 3.33 1.76 1.03
Compound Leverage Factor
-1.68 -2.07 3.48 0.96 1.95
Debt to Total Capital
322.91% 339.97% -9.93% 37.14% 0.00%
Short-Term Debt to Total Capital
4.43% 49.99% -9.73% 4.74% 0.00%
Long-Term Debt to Total Capital
318.48% 289.98% -0.19% 32.40% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 2.02% 0.00%
Common Equity to Total Capital
-222.91% -239.97% 109.93% 60.84% 100.00%
Debt to EBITDA
-1.03 -10.26 -0.02 5.45 0.00
Net Debt to EBITDA
-0.30 -9.41 0.01 4.58 0.00
Long-Term Debt to EBITDA
-1.02 -8.75 0.00 4.76 0.00
Debt to NOPAT
-88.42 134.82 -0.03 8.30 0.00
Net Debt to NOPAT
-26.13 123.71 0.01 6.97 0.00
Long-Term Debt to NOPAT
-87.21 115.00 0.00 7.24 0.00
Altman Z-Score
-4.04 0.00 0.00 0.00 452,195.72
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 4.56% 3.21% 0.00%
Liquidity Ratios
- - - - -
Current Ratio
6.72 0.20 0.46 2.36 0.00
Quick Ratio
6.22 0.11 0.09 0.37 0.00
Cash Flow Metrics
- - - - -
Free Cash Flow to Firm (FCFF)
635 -597 1,021 -1,974 0.00
Operating Cash Flow to CapEx
45.06% 2,173.36% 53.44% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
1,303.17 0.00 3,556.62 -246.28 0.00
Operating Cash Flow to Interest Expense
88.08 0.00 714.94 -7.08 -17.83
Operating Cash Flow Less CapEx to Interest Expense
-107.38 0.00 -622.97 -7.08 -17.83
Efficiency Ratios
- - - - -
Asset Turnover
0.44 0.66 0.39 0.45 3,612.87
Accounts Receivable Turnover
504.12 798.73 660.46 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.89 0.79 0.00 0.00 0.00
Accounts Payable Turnover
4.48 3.64 19.37 0.00 0.00
Days Sales Outstanding (DSO)
0.72 0.46 0.55 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
81.51 100.36 18.85 0.00 0.00
Cash Conversion Cycle (CCC)
-80.79 -99.91 -18.29 0.00 0.00
Capital & Investment Metrics
- - - - -
Invested Capital
-469 179 -425 2,073 0.01
Invested Capital Turnover
-3.52 -4.09 0.78 0.53 3,711.85
Increase / (Decrease) in Invested Capital
-648 604 -2,497 2,073 0.00
Enterprise Value (EV)
4,275 0.00 0.00 0.00 300
Market Capitalization
3,924 0.00 0.00 0.00 300
Book Value per Share
($2.94) ($1.55) ($1.09) $31.10 $0.00
Tangible Book Value per Share
($2.94) ($1.55) ($1.10) $6.43 $0.00
Total Capital
368 249 -372 2,204 0.01
Total Debt
1,188 846 37 819 0.00
Total Long-Term Debt
1,172 721 0.72 714 0.00
Net Debt
351 776 -15 687 0.00
Capital Expenditures (CapEx)
95 3.00 384 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-51 -337 -118 409 -0.00
Debt-free Net Working Capital (DFNWC)
786 -267 -65 541 -0.00
Net Working Capital (NWC)
769 -391 -102 436 -0.00
Net Nonoperating Expense (NNE)
1,302 253 670 51 7.78
Net Nonoperating Obligations (NNO)
351 776 -15 687 0.00
Total Depreciation and Amortization (D&A)
124 97 233 35 11
Debt-free, Cash-free Net Working Capital to Revenue
-10.04% -67.03% -18.38% 75.12% 0.00%
Debt-free Net Working Capital to Revenue
153.85% -53.15% -10.22% 99.31% 0.00%
Net Working Capital to Revenue
150.66% -77.91% -15.88% 80.13% 0.00%
Earnings Adjustments
- - - - -
Adjusted Basic Earnings per Share
($4.39) ($0.65) ($6.30) ($0.83) $0.00
Adjusted Weighted Average Basic Shares Outstanding
255.83M 379.86M 340.65M 316.24M 0.00
Adjusted Diluted Earnings per Share
($4.39) ($0.65) ($6.30) ($0.83) $0.00
Adjusted Weighted Average Diluted Shares Outstanding
255.83M 379.86M 340.65M 316.24M 0.00
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 ($0.83) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
294.12M 177.60M 373.80M 8.50M 0.00
Normalized Net Operating Profit after Tax (NOPAT)
-10 11 -171 125 -8.55
Normalized NOPAT Margin
-2.05% 2.14% -26.74% 22.96% -15.77%
Pre Tax Income Margin
-257.34% -48.93% -337.87% 11.58% -22.52%
Debt Service Ratios
- - - - -
EBIT to Interest Expense
-2,621.33 0.00 -7,199.64 14.40 -4.83
NOPAT to Interest Expense
-27.59 0.00 -5,145.25 12.30 -3.32
EBIT Less CapEx to Interest Expense
-2,816.80 0.00 -8,537.55 14.40 -4.83
NOPAT Less CapEx to Interest Expense
-223.06 0.00 -6,483.16 12.30 -3.32
Payout Ratios
- - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -1.47% 0.00% 0.00%

Quarterly Metrics And Ratios for Core Scientific

This table displays calculated financial ratios and metrics derived from Core Scientific's official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-55.64% -33.50% -15.54% 11.18% 49.05% 17.05% -30.55% -22.60% -37.33% -59.82% 43.69%
EBITDA Growth
135.99% -196.78% -2,726.82% -6,645.19% 42,747.75% 78.38% 95.55% 101.49% 99.83% -414.78% -10,126.32%
EBIT Growth
157.17% -139.23% -1,041.89% -8,516.31% 1,177.34% 74.57% 90.15% 98.90% 94.81% -557.91% -10,176.34%
NOPAT Growth
-177.18% -1,111.26% -242.24% -30.52% 936.81% 100.62% 97.00% 100.91% 128.45% -654.42% -8,489.92%
Net Income Growth
175.61% -35.69% -1,006.45% -8,592.18% 54,401.80% 55.00% 90.54% 98.86% 99.92% -818.68% -2,514.66%
EPS Growth
60.26% 198.08% -963.64% -22,450.00% 0.00% 50.94% 91.06% 99.20% 100.00% -524.00% -1,657.14%
Operating Cash Flow Growth
-283.09% -36.39% 5.13% -93.32% 11.19% -81.29% 110.44% -87.55% 651.65% 5.69% -15.35%
Free Cash Flow Firm Growth
78.78% 203.21% 6.50% -92.92% -122.22% -129.28% 167.74% 201.41% 239.76% 0.00% 0.00%
Invested Capital Growth
39.33% -361.96% -230.43% -29.02% 149.24% 142.17% -67.81% -130.95% -119.44% -120.49% 246.47%
Revenue Q/Q Growth
-15.74% -1.02% -32.42% -21.54% 26.71% 25.71% -11.04% 5.19% -0.49% -25.42% -0.85%
EBITDA Q/Q Growth
358.20% 43.98% 45.01% -396.69% 424.72% -433.62% -227.31% 2,033.22% 99.84% -9.91% 57.51%
EBIT Q/Q Growth
319.18% 41.03% 43.31% -450.99% 303.90% -181.47% -327.73% 56.11% 95.19% -8.98% 52.14%
NOPAT Q/Q Growth
-52.90% 3.48% -726.52% -91.65% 1,903.52% 132.66% -227.19% 24.56% 101.20% -58.48% 61.61%
Net Income Q/Q Growth
318.68% 41.67% 43.44% -482.03% 207.66% -375.61% -344.34% -2,286.60% 99.91% -0.01% 46.35%
EPS Q/Q Growth
145.10% 143.59% 74.06% -678.21% 250.00% -372.73% -450.00% 0.00% 100.00% 13.82% 50.60%
Operating Cash Flow Q/Q Growth
-394.09% 141.64% 374.50% -94.57% 2.17% 299.39% -69.87% -9.56% -82.81% 322.74% -135.94%
Free Cash Flow Firm Q/Q Growth
-120.64% -14.16% 445.71% 121.94% -0.68% -188.57% -63.72% -31.15% 32.37% 304.90% 45.70%
Invested Capital Q/Q Growth
164.55% -10.28% 25.15% -361.48% 22.41% -45.09% 174.04% 0.21% -3.94% -141.92% -28.83%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
10.33% 5.05% -0.16% 27.51% 43.18% 27.69% 13.66% 29.12% 26.34% -38.96% -16.65%
EBITDA Margin
758.06% -247.38% -437.06% -537.15% 142.05% -55.43% -13.06% 9.12% -0.50% -300.10% -203.64%
Operating Margin
-53.56% -42.15% -43.23% 4.66% 30.71% 2.77% -10.67% 7.46% 6.30% -524.60% -246.89%
EBIT Margin
727.71% -279.75% -469.55% -559.78% 125.13% -77.76% -34.73% -7.22% -17.31% -357.90% -244.94%
Profit (Net Income) Margin
730.20% -281.35% -477.44% -570.44% 117.16% -137.88% -36.44% -7.30% -0.32% -358.64% -267.45%
Tax Burden Percent
99.96% 100.14% 100.03% 100.02% 99.90% 100.17% 100.28% 101.41% 136.62% 95.29% 102.51%
Interest Burden Percent
100.38% 100.43% 101.65% 101.89% 93.72% 177.01% 104.65% 99.61% 1.36% 105.16% 106.51%
Effective Tax Rate
0.04% 0.00% 0.00% 0.00% 0.10% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-84.61% 0.00% 0.00% 0.00% 0.00% 0.00% -5.37% 5.65% 2.74% -285.33% -217.36%
ROIC Less NNEP Spread (ROIC-NNEP)
37.59% 0.00% 0.00% 0.00% 0.00% 0.00% -9.26% 2.33% 1.71% -282.23% -250.14%
Return on Net Nonoperating Assets (RNNOA)
-76.69% 0.00% 0.00% 0.00% 0.00% 0.00% 45.11% 93.18% 2.65% -194.21% -639.58%
Return on Equity (ROE)
-161.30% 185.59% 216.90% 112.58% 9.74% 48.99% 39.74% 98.83% 5.39% -479.54% -856.93%
Cash Return on Invested Capital (CROIC)
-64.37% 0.00% 0.00% 0.00% -284.87% -333.65% 36.61% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
245.16% -123.64% -322.14% -426.24% 89.29% -51.41% -15.86% -2.96% -5.68% -141.18% -229.65%
Return on Assets (ROA)
246.00% -124.34% -327.55% -434.35% 83.60% -91.16% -16.64% -2.99% -0.11% -141.47% -250.74%
Return on Common Equity (ROCE)
-161.30% 185.59% 216.90% 112.58% 9.74% 48.99% 39.74% 98.83% 5.39% -457.69% -51.36%
Return on Equity Simple (ROE_SIMPLE)
520.64% 0.00% 170.71% 76.67% 11.12% 0.00% 115.98% 224.06% 411.12% 0.00% -2,260.76%
Net Operating Profit after Tax (NOPAT)
-43 -28 -29 4.61 55 2.75 -8.43 6.63 5.32 -445 -281
NOPAT Margin
-53.54% -29.51% -30.26% 3.26% 30.68% 1.94% -7.47% 5.22% 4.41% -367.22% -172.82%
Net Nonoperating Expense Percent (NNEP)
-122.20% 42.18% 81.31% 346.20% -61.81% 52.17% 3.88% 3.31% 1.03% -3.10% 32.79%
Return On Investment Capital (ROIC_SIMPLE)
-4.25% -7.57% - - - 1.11% - - - 119.57% -
Cost of Revenue to Revenue
89.67% 95.53% 100.16% 72.49% 56.52% 72.31% 86.34% 70.88% 73.66% 138.96% 116.65%
SG&A Expenses to Revenue
50.44% 37.83% 36.03% 18.60% 7.86% 17.08% 20.82% 19.22% 18.04% 32.08% 26.66%
R&D to Revenue
0.00% 5.31% 2.98% 1.54% 1.00% 1.32% 2.00% 1.29% 1.17% 2.19% 3.81%
Operating Expenses to Revenue
63.89% 46.62% 43.06% 22.85% 12.77% 24.92% 24.32% 21.66% 20.04% 485.64% 230.24%
Earnings before Interest and Taxes (EBIT)
579 -264 -448 -790 225 -110 -39 -9.17 -21 -434 -398
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
603 -233 -417 -758 255 -79 -15 12 -0.60 -364 -331
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
5.18 7.68 5.49 2.87 1.12 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
8.63 0.00 0.00 0.00 5.36 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
6.36 8.37 6.03 3.77 2.07 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 6.71 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 17.57 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 196.14 57.71 29.40 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 99.65 66.28 42.94 17.29 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 6.74 4.38 13.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
-6.52 -1.45 -0.76 -0.57 -2.04 -1.42 -2.02 -0.07 -0.09 -0.09 13.39
Long-Term Debt to Equity
-6.43 -1.43 -0.74 -0.55 -1.97 -1.21 -1.71 0.00 0.00 0.00 0.00
Financial Leverage
-2.04 -0.80 -0.91 -0.32 -0.69 -0.76 -4.87 39.93 1.55 0.69 2.56
Leverage Ratio
-4.88 -1.63 -1.42 -1.02 -2.16 -1.51 -6.10 108.12 4.82 3.33 4.77
Compound Leverage Factor
-4.90 -1.64 -1.44 -1.04 -2.03 -2.67 -6.39 107.69 0.07 3.50 5.08
Debt to Total Capital
118.12% 322.91% -325.26% -130.06% 196.06% 339.97% 198.27% -7.91% -9.86% -9.93% 93.05%
Short-Term Debt to Total Capital
1.62% 4.43% -10.46% -3.90% 7.04% 49.99% 30.11% -7.62% -9.58% -9.73% 93.05%
Long-Term Debt to Total Capital
116.50% 318.48% -314.80% -126.16% 189.02% 289.98% 168.15% -0.30% -0.28% -0.19% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
-18.12% -222.91% 425.26% 230.06% -96.06% -239.97% -98.27% 107.91% 109.86% 109.93% 6.95%
Debt to EBITDA
-1.47 -1.03 -0.56 -1.03 3.74 -10.26 -2.30 -0.04 -0.02 -0.02 -0.72
Net Debt to EBITDA
-0.60 -0.30 -0.30 -0.87 3.09 -9.41 -2.12 0.07 0.02 0.01 -0.69
Long-Term Debt to EBITDA
-1.45 -1.02 -0.54 -1.00 3.61 -8.75 -1.95 0.00 0.00 0.00 0.00
Debt to NOPAT
-14.44 -88.42 32.50 16.30 16.41 134.82 -1.91 -0.04 -0.03 -0.03 -1.02
Net Debt to NOPAT
-5.91 -26.13 17.72 13.72 13.53 123.71 -1.77 0.07 0.02 0.01 -0.98
Long-Term Debt to NOPAT
-14.24 -87.21 31.46 15.81 15.82 115.00 -1.62 0.00 0.00 0.00 0.00
Altman Z-Score
-0.11 -1.95 -4.89 -7.60 -1.86 0.00 0.00 0.00 0.00 0.00 0.00
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.56% 94.01%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.26 6.72 3.63 1.58 1.04 0.20 0.43 0.59 0.47 0.46 0.17
Quick Ratio
3.58 6.22 3.39 1.35 0.72 0.11 0.14 0.31 0.22 0.09 0.03
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-128 620 723 132 -603 -601 678 1,870 2,717 2,052 -1,002
Operating Cash Flow to CapEx
-45.90% 47.62% 18.33% 38.41% 69.52% 186.48% 189.47% 1,900.42% 1,295.78% 82.71% -997.93%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 2,279.39 1,103.41 -12,069.80 -561.60 0.00 0.00 0.00 7,150.46 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 18.02 10.03 443.48 20.28 0.00 0.00 0.00 404.13 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 -80.32 -16.09 -194.40 9.41 0.00 0.00 0.00 -84.46 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.34 0.44 0.69 0.76 0.71 0.66 0.46 0.41 0.33 0.39 0.94
Accounts Receivable Turnover
386.74 504.12 151.83 194.02 876.10 798.73 230.49 222.52 1,659.71 660.46 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.67 0.89 1.02 0.99 0.93 0.79 0.57 0.64 0.79 0.00 0.00
Accounts Payable Turnover
31.95 4.48 15.46 12.94 11.78 3.64 9.98 12.60 18.14 19.37 28.14
Days Sales Outstanding (DSO)
0.94 0.72 2.40 1.88 0.42 0.46 1.58 1.64 0.22 0.55 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
11.43 81.51 23.62 28.22 30.99 100.36 36.57 28.97 20.13 18.85 12.97
Cash Conversion Cycle (CCC)
-10.48 -80.79 -21.21 -26.33 -30.57 -99.91 -34.99 -27.33 -19.91 -18.29 -12.97
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
303 -469 -425 -568 217 179 326 -440 -441 -425 1,013
Invested Capital Turnover
1.58 -3.52 -11.25 -1.14 -5.01 -4.09 0.72 1.08 0.62 0.78 1.26
Increase / (Decrease) in Invested Capital
85 -648 -751 -128 659 604 -687 -1,864 -2,711 -2,497 721
Enterprise Value (EV)
2,614 4,275 3,367 2,169 1,165 0.00 0.00 0.00 0.00 0.00 0.00
Market Capitalization
2,129 3,924 3,063 1,653 629 0.00 0.00 0.00 0.00 0.00 0.00
Book Value per Share
($0.62) ($2.94) ($2.82) ($6.10) ($1.79) ($1.55) ($1.09) ($1.04) ($1.09) ($1.09) $0.20
Tangible Book Value per Share
($0.62) ($2.94) ($2.82) ($6.10) ($1.81) ($1.55) ($1.10) ($1.05) ($1.10) ($1.10) $0.20
Total Capital
1,002 368 -172 -471 332 249 426 -364 -372 -372 1,051
Total Debt
1,183 1,188 558 613 650 846 845 29 37 37 978
Total Long-Term Debt
1,167 1,172 540 594 627 721 717 1.08 1.06 0.72 0.00
Net Debt
484 351 304 516 536 776 781 -48 -33 -15 940
Capital Expenditures (CapEx)
88 29 31 3.14 32 12 2.87 0.95 1.54 140 5.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-45 -51 -35 -36 -86 -337 -114 -125 -148 -118 -135
Debt-free Net Working Capital (DFNWC)
654 786 219 61 29 -267 -50 -48 -79 -65 -98
Net Working Capital (NWC)
638 769 201 43 5.18 -391 -178 -76 -115 -102 -1,075
Net Nonoperating Expense (NNE)
-623 238 426 810 -156 198 33 16 5.71 -10 154
Net Nonoperating Obligations (NNO)
484 351 304 516 536 776 745 -48 -33 -15 940
Total Depreciation and Amortization (D&A)
24 31 31 32 30 32 24 21 20 70 67
Debt-free, Cash-free Net Working Capital to Revenue
-10.91% -10.04% -6.18% -6.20% -15.27% -67.03% -23.57% -23.57% -26.07% -18.38% -16.50%
Debt-free Net Working Capital to Revenue
159.13% 153.85% 39.28% 10.67% 5.08% -53.15% -10.30% -9.12% -13.88% -10.22% -11.92%
Net Working Capital to Revenue
155.19% 150.66% 36.07% 7.48% 0.92% -77.91% -36.94% -14.34% -20.15% -15.88% -131.01%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$1.44 $0.38 ($1.17) ($4.51) $0.91 ($0.52) ($0.11) ($0.02) ($0.03) ($1.06) ($1.23)
Adjusted Weighted Average Basic Shares Outstanding
315.19M 255.83M 292.49M 178.51M 230.95M 379.86M 382.48M 375.78M 375.42M 340.65M 354.20M
Adjusted Diluted Earnings per Share
$1.25 $0.51 ($1.17) ($4.51) $0.78 ($0.52) ($0.11) ($0.02) ($0.03) ($1.06) ($1.23)
Adjusted Weighted Average Diluted Shares Outstanding
363.31M 255.83M 292.49M 178.51M 282.53M 379.86M 382.48M 375.78M 375.42M 340.65M 354.20M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
297.82M 294.12M 279.25M 258.22M 177.78M 177.60M 386.02M 382.61M 376.57M 373.80M 374.53M
Normalized Net Operating Profit after Tax (NOPAT)
-43 -28 -28 4.42 59 6.49 -7.97 6.89 5.32 -63 -54
Normalized NOPAT Margin
-53.54% -29.40% -29.89% 3.13% 32.80% 4.58% -7.06% 5.43% 4.41% -51.88% -33.01%
Pre Tax Income Margin
730.46% -280.95% -477.30% -570.33% 117.27% -137.64% -36.34% -7.19% -0.24% -376.36% -260.90%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 -1,412.42 -6,582.14 4,500.68 -103.15 0.00 0.00 0.00 -1,512.05 0.00
NOPAT to Interest Expense
0.00 0.00 -91.02 38.38 1,103.46 2.57 0.00 0.00 0.00 -1,551.41 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 -1,510.76 -6,608.27 3,862.80 -114.02 0.00 0.00 0.00 -2,000.63 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 -189.36 12.25 465.58 -8.30 0.00 0.00 0.00 -2,040.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.47% 0.00%

Frequently Asked Questions About Core Scientific's Financials

When does Core Scientific's fiscal year end?

According to the most recent income statement we have on file, Core Scientific's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Core Scientific's net income changed over the last 4 years?

Core Scientific's net income appears to be on an upward trend, with a most recent value of -$1.32 billion in 2024, rising from -$12.21 million in 2020. The previous period was -$246.49 million in 2023. See Core Scientific's forecast for analyst expectations on what’s next for the company.

What is Core Scientific's operating income?
Core Scientific's total operating income in 2024 was -$19.20 million, based on the following breakdown:
  • Total Gross Profit: $121.07 million
  • Total Operating Expenses: $140.27 million
How has Core Scientific revenue changed over the last 4 years?

Over the last 4 years, Core Scientific's total revenue changed from $54.19 million in 2020 to $510.67 million in 2024, a change of 842.3%.

How much debt does Core Scientific have?

Core Scientific's total liabilities were at $2.42 billion at the end of 2024, a 84.8% increase from 2023, and a 604,748,650.0% increase since 2020.

How much cash does Core Scientific have?

In the past 4 years, Core Scientific's cash and equivalents has ranged from $0.00 in 2020 to $836.20 million in 2024, and is currently $836.20 million as of their latest financial filing in 2024.

How has Core Scientific's book value per share changed over the last 4 years?

Over the last 4 years, Core Scientific's book value per share changed from 0.00 in 2020 to -2.94 in 2024, a change of -2,937,100.0%.



This page (NASDAQ:CORZ) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners